HIGHLIGHTS
- who: Margaux Sevin from the University of Basel, Basel , Switzerland, Cypath, Dijon, France. have published the paper: HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
- what: The authors show that specific inhibition of HSP27 using OGX-427 limits myelofibrosis progression in two murine models of MF15, 22, 23 and affects the JAK2/STAT signalling pathway. The authors demonstrated that another essential chaperone, HSP27, is a therapeutic target of remarkable interest. The authors show that HSP27 is involved in the proliferation of JAK2V617F . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.